RET and non-small cell lung carcinoma: A retrospective analysis of multicenter clinical trial containing 165 RET‐positive NSCLC patients showed that the response rates (partial or complete) to cabozantinib, vandetanib, and sunitinib were 37%, 18%, and 22%, respectively.